Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-01-02 Sale |
2025-01-03 4:15 pm |
Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer |
6,954 | $0.9837 | $6,841 | 321,546 (Direct) |
View |
| 2025-01-02 Sale |
2025-01-03 4:15 pm |
Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING |
1,803 | $0.9837 | $1,774 | 78,197 (Direct) |
View |
| 2024-12-18 Purchase |
2024-12-19 4:19 pm |
Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner |
1,759,978 | $1.04 | $1,830,377 | 19,080,717 (Direct) |
View |
| 2024-04-02 Purchase |
2024-04-03 6:50 pm |
Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner |
485,250 | $0.76 | $368,790 | 11,227,923 (Direct) |
View |
| 2024-02-08 Sale |
2024-02-09 4:33 pm |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner |
1,000 | $0.64 | $640 | 2,754,109 (Indirect Direct) |
View |
| 2024-01-11 Sale |
2024-01-16 6:16 pm |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner |
4,235 | $0.85017 | $3,600 | 2,755,109 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-06-11 Option Award |
2025-06-12 4:37 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-11 Option Award |
2025-06-12 4:37 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | Brennan Aoife Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-11 Option Award |
2025-06-12 4:36 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | Bonstein Sara Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-11 Option Award |
2025-06-12 4:36 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | Curran Daniel J. Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-11 Option Award |
2025-06-12 4:36 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-11 Option Award |
2025-06-12 4:35 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | Xu Yuan Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-11 Option Award |
2025-06-12 4:35 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | Shannon James Samuel Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-11 Option Award |
2025-06-12 4:34 pm |
N/A 2035-06-10 |
Xilio Therapeutics Inc. | XLO | Rossi Christina Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2025-06-10 Option Award |
2025-06-12 4:34 pm |
N/A 2035-06-09 |
Xilio Therapeutics Inc. | XLO | Bello Akintunde Olatokumbo Director |
62,000 | $0 | 62,000 (Direct) |
View |
| 2025-04-15 Option Award |
2025-04-16 4:30 pm |
N/A 2035-04-14 |
Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO |
190,000 | $0 | 190,000 (Direct) |
View |
| 2025-04-15 Option Award |
2025-04-16 4:30 pm |
N/A 2035-04-14 |
Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer |
75,000 | $0 | 75,000 (Direct) |
View |
| 2025-01-01 Option Award |
2025-01-03 4:15 pm |
N/A 2035-12-31 |
Xilio Therapeutics Inc. | XLO | Luptakova Katarina CHIEF MEDICAL OFFICER |
200,000 | $0 | 266,500 (Direct) |
View |
| 2025-01-01 Exercise |
2025-01-03 4:15 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Luptakova Katarina CHIEF MEDICAL OFFICER |
16,625 | $0 | 266,500 (Direct) |
View |
| 2025-01-01 Option Award |
2025-01-03 4:15 pm |
N/A 2035-12-31 |
Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer |
251,000 | $0 | 321,546 (Direct) |
View |
| 2025-01-01 Exercise |
2025-01-03 4:15 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Financial Officer |
19,375 | $0 | 321,546 (Direct) |
View |
| 2025-01-01 Option Award |
2025-01-03 4:15 pm |
N/A 2035-12-31 |
Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING |
60,000 | $0 | 78,197 (Direct) |
View |
| 2025-01-01 Exercise |
2025-01-03 4:15 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING |
5,000 | $0 | 78,197 (Direct) |
View |
| 2025-01-01 Option Award |
2025-01-03 4:15 pm |
N/A 2035-12-31 |
Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO |
638,000 | $0 | 1,015,633 (Direct) |
View |
| 2025-01-01 Exercise |
2025-01-03 4:15 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO |
44,250 | $0 | 1,015,633 (Direct) |
View |
| 2024-10-01 Option Award |
2024-10-02 5:15 pm |
N/A 2034-09-30 |
Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING |
26,000 | $0 | 26,000 (Direct) |
View |
Ownership |
2024-09-27 9:00 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Chudnovsky Yekaterina GKCC LLC 10% Owner |
0 | $0 | 7,000,000 (Indirect) |
View |
| 2024-08-03 Option Award |
2024-08-06 8:00 pm |
N/A 2034-08-02 |
Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Operating Officer |
52,000 | $0 | 52,000 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-17 4:30 pm |
N/A 2034-06-13 |
Xilio Therapeutics Inc. | XLO | Xu Yuan Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-17 4:30 pm |
N/A 2034-06-13 |
Xilio Therapeutics Inc. | XLO | Bonstein Sara Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-17 4:30 pm |
N/A 2034-06-13 |
Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-17 4:30 pm |
N/A 2034-06-13 |
Xilio Therapeutics Inc. | XLO | Rossi Christina Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-17 4:30 pm |
N/A 2034-06-13 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-17 4:30 pm |
N/A 2034-06-13 |
Xilio Therapeutics Inc. | XLO | Curran Daniel J. Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2024-06-13 Option Award |
2024-06-17 4:12 pm |
N/A 2034-06-12 |
Xilio Therapeutics Inc. | XLO | Shannon James Samuel Director |
50,000 | $0 | 50,000 (Direct) |
View |
| 2024-06-13 Option Award |
2024-06-17 4:10 pm |
N/A 2034-06-12 |
Xilio Therapeutics Inc. | XLO | Brennan Aoife Director |
50,000 | $0 | 50,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-03 4:10 pm |
N/A 2034-04-30 |
Xilio Therapeutics Inc. | XLO | Luptakova Katarina CHIEF MEDICAL OFFICER |
59,333 | $0 | 59,333 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-03 4:10 pm |
N/A 2034-04-30 |
Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING |
20,000 | $0 | 20,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-03 4:10 pm |
N/A 2034-04-30 |
Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James CHIEF OPERATING OFFICER |
208,000 | $0 | 208,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-03 4:10 pm |
N/A 2034-04-30 |
Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO |
474,000 | $0 | 474,000 (Direct) |
View |
Ownership |
2024-04-03 6:48 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner |
0 | $0 | 6,860,223 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 4:38 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James CHIEF OPERATING OFFICER |
77,500 | $0 | 77,500 (Direct) |
View |